Risk factors for increased cost of exacerbations of chronic bronchitis and chronic obstructive pulmonary disease;Factores de riesgo de elevado coste de las agudizaciones de la bronquitis crónica y la EPOC

Archivos de Bronconeumologia

Volumn 42, Issue 4, 2006, Pages 175-182

  Llor, C ^a   Naberan, K ^b   Cots, J M ^a   Molina, J ^c   Ros, F ^d   Miravitlles, M ^e  

^a Grupo de Infecciosas de la Sociedad Catalana de Medicina Familiar

^b Grupo de Neumología de la Sociedad Catalana de Medicina Familiar

^c Grupo de Respiratorio en Atención Primaria GRAP

^d Bayer Healthcare   (Spain)

^e HOSPITAL CLÍNIC   (Spain)

Author keywords

Antibiotics; Chronic bronchitis; COPD; Costs; Exacerbations; Pharmacoeconomics

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CLARITHROMYCIN; MOXIFLOXACIN;

ADULT; AGED; ARTICLE; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; COST OF ILLNESS; DISEASE EXACERBATION; EMERGENCY WARD; FOLLOW UP; HEALTH CARE COST; HOSPITAL COST; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; OXYGEN THERAPY; RISK FACTOR; THERAPY EFFECT;

EID: 33646516850     PISSN: 03002896     EISSN: None     Source Type: Journal    
DOI: 10.1157/13086623     Document Type: Article

References (30)

1. Sobradillo Peña V, Miravitlles M, Gabriel R, Jimeńez CA, Villasante C, Masa JF, et al. Geographical variations in prevalence and underdiagnosis of COPD. Results of the IBERPOC multicentre epidemiological study. Chest. 2000;118:981-9.
2. Peris Cardells R, Rico Salvador I, Herrera de Pablo P, Pérez Jiménez A, Sánchez-Toril Lopez F, Pérez Fernández JA. Estudio demográfico del tabaquismo en el Área de Salud 5 de Valencia. Arch Bronconeumol. 2004;40:160-5.
3. Davey PG, Malek MM, Parker SE. Pharmacoeconomics of antibacterial treatment. Pharmacoeconomics. 1992;1:409-37.
4. Miravitlles M, Mayordomo C, Artés T, Sánchez-Agudo L, Nicolau F, Segú JL, and the EOLO Group. Treatment of chronic obstructive pulmonary disease and its exacerbations in general practice. Respir Med. 1999;93;173-9.
5. Miravitlles M, Murio C, Guerrero T, Gisbert R on behalf of the DAFNE study group. Costs of chronic bronchitis and COPD. A one year follow-up study. Chest. 2003;123:784-91.
6. Masa JF, Sobradillo V, Villasante C, Jiménez-Ruiz CA, Fernández-Fau L, Viejo JL, et al. Costes de la EPOC en España. Estimación a partir de un estudio epidemiológico poblacional. Arch Bronconeumol. 2004;40:72-9.
7. Miravitlles M, Murio C, Guerrero T, Gisbert R on behalf of the DAFNE study group. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest. 2002;121:1449-55.
8. Llor C, Naberan K, Cots JM, Molina J, Miravitlles M. Economic evaluation of the antibiotic treatment of exacerbations of chronic bronchitis and COPD in primary care. Int J Clin Pract. 2004;58:937-44.
9. Álvarez-Sala JL, Cimas E, Masa JF, Miravitlles M, Molina J, Naberan K, et al. Recomendaciones para la atención al paciente con enfermedad pulmonar obstructiva crónica. Arch Bronconeumol. 2001;37:269-78.
10. Roca J, Sanchis J, Agustí-Vidal A, Segarra F, Navajas D, Rodríguez R, et al. Spirometric reference values from a Mediterranean population. Bull Eur Pysiopthol Respir. 1986;22:217-24.
11. Anthonisen NR, Manfreda J, Warren CPW, Hershfield ES, Harding GKM, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106:196-204.
12. Álvarez F, Bouza E, García-Rodríguez JA, Mensa J, Monsó E, Picazo JJ, et al. Segundo documento de consenso sobre uso de antimicrobianos en la exacerbación de la enfermedad pulmonar obstructiva crónica. Arch Bronconeumol. 2003;39:274-82.
13. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999;54:581-6.
14. Miravitlles M, Llor C, Naberan K, Cots JM en representación del estudio EFEMAP. Utilización de Internet en un estudio multicéntrico sobre EPOC en atención primaria. Fase piloto del estudio EFEMAP. Arch Bronconeumol. 2002;38:427-30.
15. Hosmer DW, Lemeshow S. Applied logistic regression. New York: John Wiley & Sons Inc.; 1989.
16. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143:29-36.
17. Medicom S.A. Vademécum Internacional. Madrid: Medi Medic; 2002.
18. Giantz SA, Slinker BK. Primer of applied regression and analysis of variance. New York: McGraw-Hill International Book Co.; 1990. p. 512-68.
19. MacFarlane JT, Colville A, Guion A, MacFarlane RM, Rose DH. Estudio prospectivo sobre etiología y evolución de las infecciones respiratorias bajas extrahospitalarias en el adulto. Lancet (Ed. Esp). 1993;23:12-5.
20. Miravitlles M, Murio C, Guerrero T on behalf of the DAFNE Study Group. Factors associated with relapse after ambulatory treatment of acute exacerbations of chronic bronchitis. A prospective multicenter study in the community. Eur Respir J. 2001;17:928-33.
21. Adams SG, Melo J, Luther M, Anzueto A. Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD. Chest. 2000;117:1345-52.
22. Kim S, Emerman CL, Cydulka RK, Rowe BH, Clark S, Camargo CA. Prospective multicenter study of relapse following emergency department treatment of COPD exacerbation. Chest. 2004;125:473-81.
23. Dewan NA, Rafique S, Kanwar B, et al. Acute exacerbation of COPD. Factors associated with poor outcome. Chest. 2000;117:662-71.
24. Oostenbrink JB, Rutten-van-Mölken MP. Resource use and risk factors in high-cost exacerbations of COPD. Respir Med. 2004;98:883-91.
25. Miravitlles M, Espinosa C, Fernández-Laso E, Martos JA, Maldonado JA, Gallego M and Study Group of Bacterial Infection in COPD. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Chest. 1999;116:40-6.
26. Sacristán JA, Soto J, Reviriego J, Galende I. Farmacoeconomía: el cálculo de la eficiencia. Med Clin (Barc). 1994;103:143-9.
27. Miravitlles M, Llor C, Naberan K, Cots JM, Molina J for the EFEMAP study group. The effect of various antimicrobial regimens on the clinical course of exacerbations of chronic bronchitis and chronic obstructive pulmonary disease in Primary Care. Clin Drug Invest. 2004;24:63-72.
28. Miravitlles M, Llor C, Naberan K, Cots JM, Molina J. Variables associated with recovery from acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease, Respir Med. 2005;99:955-65.
29. Miravitlles M, Zalacain R, Murio C, Álvarez-Sala JL, Masa JF, Verea H, et al, on Behalf of the IMPAC study group. Speed of recovery from acute exacerbations of COPD after treatment with antimicrobials: results of a two-year study. Clin Drug Invest. 2003;23:439-50.
30. Llor C, Naberan K. ¿Existe evidencia de tratar con antibióticos las agudizaciones de la enfermedad pulmonar obstructiva crónica leve? FMC. 2003;10:454-60.